genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
Genedrive enters distribution agreement with Mountain Horse Solutions
New clinical guidance in the UK supports assay
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces the first shipments to the United States of its Genedrive® 96 SARS-CoV-2 Kits.
Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, confirms that its Genedrive 96 SARS CoV-2 Kit continues to detect all known variants of COVID-19, including the newest variants released
Genedrive notifies FDA of its intent to distribute to SARS-CoV-2 PCR test in the USA
Hepatitis C virus testing kit reveals 100% sensitivity and specificity when compared to Abbott Realtime HCV test
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2020 on Tuesday 17 November 2020.
Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it has completed the assay design for the Company’s Point-of-Care (“POC”) solution for COVID-19 testing and is now generating
Genedrive® 96 SARS-CoV-2 Kit verified with Beckman Coulter Life Sciences RNA extraction chemistry